Innovations and Challenges in Renal Cancer
Online CME Activity
This activity is published in the journal Clinical Cancer Research, Vol 13 (2 Suppl), pp 1s-4s, Jan 15, 2007: "Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference"
Up to 2 hours of AMA PRA Category 1 Credit™
Release date: January 2007 Valid through: January 2009
Course Material: CME Activity - PDF
Receiving CME Credit
To receive online CME credit for this activity, click below to complete the registration, test and evaluation.
You will have 2 opportunities to answer the questions correctly. Then you will be shown answers to any questions answered incorrectly, to be sure you understand the material. You will be able to print your CME certificate immediately following completion of the test and evaluation.
Target Audience
This activity is designed to meet the educational needs of oncologists and other medical professionals who assess and treat patients with renal cancer.
Educational Objectives
Following participation in this CME activity, participants should be able to:
- Review important aspects of renal cancer genetics and biology as they relate to prognosis and therapy
- Assess current and potential future roles of primary adjuvant, immunotherapeutic and targeted agents in renal cancer
- Assess recent advances in monitoring targeted therapies
Educational Need
Several important new technologies and therapies are currently in development for renal cancer, and a great deal of new clinical information is becoming available, with potentially significant implications for disease management. There is a clear need for oncologists and other medical professionals who assess and treat patients with renal cancer to be aware of recent advances and recommendations for the field including: new ways biology is informing approaches to prognosis and therapy; staging and prognostic classification; available and emerging therapies; and recommendations for advancing clinical research.
Sponsorship and Accreditation
This journal-based CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. (InforMEDical). InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.
Educational Grant Support
This educational proceedings publication is based on a symposium held March 24-25, 2006, in Cambridge, Massachusetts, USA. The program was made possible by educational grants provided by Bayer Healthcare Pharmaceuticals / Onyx Pharmaceuticals, Chiron Corporation, Genentech, Pfizer, Inc., Schering Plough, Wyeth Pharmaceuticals, and the Kidney Cancer Association.
Credit Designation
InforMEDical designates this activity for up to 2.0 AMA PRA Category 1 Credits™. Each physician should claim credit commensurate with the extent of their participation in the activity.
Financial Disclosure
The program faculty have reported the following financial relationships with commercial pharmaceutical, device and/or biotechnology companies: Michael B. Atkins: Bayer: consulting, Speakers’ Bureau; Chiron: consulting, Speakers’ Bureau; Genetech: consulting; Pfizer: Speakers’ Bureau; Wyeth: consulting. Marc S. Ernstoff: Bayer: research support; Berlex: research support, Speakers’ Bureau; Bristol-Myers Squibb: research support; Chiron: research support, Speakers’ Bureau; NIH: research support; Pfizer: Speaker’s Bureau. Robert A. Figlin: Nothing to disclose. Keith T. Flaherty: Bayer: Speakers’ Bureau; Genentech: advisory board. Daniel J. George: Novartis: consultant, Speakers’ Bureau, research support; Pfizer: consultant, Speakers’ Bureau, research support. William G. Kaelin, Jr.: Novartis: consultant, unrestricted gift; Pfizer: unrestricted gift. Eugene D. Kwon: Nothing to disclose. Towia Liberman: Nothing to disclose. W. Marston Linehan: Nothing to disclose. David F. McDermott: Chiron: Speakers’ Bureau; Genentech: advisory board; Onyx/Bayer: advisory board. Augusto C. Ochoa: Nothing to disclose. Allan J. Pantuck: Chiron: consultant, research support; Wyeth: research support. Brian I. Rini: Bayer: consultant research support; Genentech: consultant research support; Pfizer: consultant research support. Mark A. Rosen: Nothing to disclose. Jeffrey A. Sosman: Bayer: consultant, research support; Vikas P. Sukhatme: Nothing to disclose. Johannes W. Vieweg: Geron: consultant; Christopher G. Wood: Antigenics: advisory board.